Literature DB >> 29685060

Comparisons of therapies in different scenarios help complete the puzzle.

Tomas Kalincik1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29685060     DOI: 10.1177/1352458518771846

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  1 in total

1.  Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

Authors:  Timothy Spelman; William L Herring; Thibaut Dort; Yuanhui Zhang; Michael Tempest; Isobel Pearson; Ulrich Freudensprung; Carlos Acosta; Robert Hyde; Eva Havrdova; Dana Horakova; Maria Trojano; Giovanna De Luca; Alessandra Lugaresi; Guillermo Izquierdo; Pierre Grammond; Pierre Duquette; Raed Alroughani; Eugenio Pucci; Franco Granella; Jeannette Lechner-Scott; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Csilla Rozsa; Cavit Boz; Raymond Hupperts; Vincent Van Pesch; Celia Oreja-Guevara; Anneke van der Walt; Vilija G Jokubaitis; Tomas Kalincik; Helmut Butzkueven
Journal:  Pharmacoeconomics       Date:  2021-12-18       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.